drugset / Trial / NCT02728349

Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma

NCT02728349

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study: Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the advanced Glioblastoma Patients ;

Timeline

Start
2016-04-12
Primary completion
2017-08-23
Completion
2017-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorogenic acid Small molecule

Indications